QuidelOrtho (QDEL) is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
- QuidelOrtho Completes Major Debt Refinancing Transaction
- QuidelOrtho’s Earnings Call: Mixed Sentiment with Global Growth
- Cautious Optimism: QuidelOrtho’s Hold Rating Amid Market Challenges and Margin Growth Potential
- QuidelOrtho price target lowered to $55 from $60 at Raymond James
- QuidelOrtho price target lowered to $40 from $50 at Citi